Dihydro-β-erythroidine hydrobromide

Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities[1][2][3].

Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR

Signaling Pathways >> Neuronal Signaling >> nAChR

Research Areas >> Neurological Disease

Dihydro-Beta-Erythroidine hydrobromide (DHβE hydrobromide; 10 nmol/0.5 μL) is infused into the respective areas prior to a systemic nicotine injection (0.2 mg/kg; SC). DHβE infused into the ventral tegmental area (VTA), nucleus accumbens (NAcc), or infralimbic (IL) cortex, but not prelimbic (PrL) cortex, attenuated nicotine-enhanced responding for a conditioned reinforcer (CRf)[2]. The co-administration of Dihydro-Beta-Erythroidine hydrobromide (5.0 mg/kg; s.c) with nicotine (0.2 and 0.4 mg/kg; s.c.) prevents the development of conditioned taste aversions (CTAs)[4]. Animal Model: Male hooded Lister rats[4] Dosage: 0.5, 1.6 and 5.0 mg/kg Administration: S.c. Result: A complete blockade of the nicotine effect produced by the training dose of nicotine (0.2 mg/kg).

[1]. Harvey SC, et al. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem. 1996 Nov;67(5):1953-9.

[2]. Tabbara RI, et al. Nicotine enhances responding for conditioned reinforcement via α4β2 nicotinic acetylcholine receptors in the ventral tegmental area, but not the nucleus accumbens or the prefrontal cortex. Neuropharmacology. 2019 Apr;148:68-76.

[3]. Clementson S, et al. Enantioselective Total Synthesis of (+)-Dihydro-β-erythroidine. J Am Chem Soc. 2019 Jun 5;141(22):8783-8786.

MOLECULAR FORMULA :

C16-H21-N-O3.Br-H

MOLECULAR WEIGHT :

356.30

WISWESSER LINE NOTATION :

T B6656 1A Q AX DVO JN XU XUTJ PO1 &EH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

30 mg/kg

TOXIC EFFECTS :

Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - changes in structure or function of salivary glands

REFERENCE :

JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 75,270,1942

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

8900 ug/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 82,266,1944

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

1100 ug/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 82,266,1944

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - rabbit

DOSE/DURATION :

2100 ug/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

REFERENCE :

JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 82,266,1944